ATLASAvalo Therapeutics (AVTX) earnings date: Nov 5, 2026
Avalo Therapeutics (AVTX) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026. Analysts expect EPS of -$0.63.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on AVTX
| Last price | $7.30 (+1.8%) |
|---|---|
| Normal 1-day range (±1σ) | ±9.2% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Avalo Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Avalo Therapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Avalo Therapeutics. You can switch it off at any time.
Alert me before AVTX reportsFree to start. Creating an account takes under a minute.
Notify me when Avalo Therapeutics reports
Track AVTX free Add Avalo Therapeutics to a free ATLAS watchlist and see its next report date in one place.
AVTX earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.63 |
| Last report | Aug 6, 2026 · Miss |
| Beat rate (last 4 reports) | 2 of 4 (50%) |
| Average EPS surprise | +4.1% |
| Average move around a report | ±3.8% (last 4) |
| Sector | Healthcare · Biotechnology |
Avalo Therapeutics earnings history: last 4 reports
Avalo Therapeutics last reported on Aug 6, 2026: EPS of -$0.83 against an estimate of -$0.62 (-33.9% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 6, 2026 | -$0.62 | -$0.83 | -33.9% | Miss | -2.8% |
| May 13, 2026 | -$1.03 | -$0.98 | +4.9% | Beat | -4.7% |
| Mar 23, 2026 | -$1.49 | -$0.37 | +75.2% | Beat | +0.2% |
| Mar 2, 2026 | -$0.54 | -$0.70 | -29.6% | Miss | +7.7% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for AVTX
See the fair value, the probability range and the earnings history of Avalo Therapeutics on its ATLAS page.
Avalo Therapeutics (AVTX) stock analysisPlans from €3.99 a month.
Avalo Therapeutics earnings: frequently asked questions
When does Avalo Therapeutics (AVTX) report earnings?
Avalo Therapeutics is scheduled to report on Thursday, November 5, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for AVTX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.63 per share (USD). Estimates can change before the report.
How often does AVTX beat earnings estimates?
Of its last 4 reports with a recorded result, Avalo Therapeutics beat the EPS estimate 2 times; the average surprise was +4.1%. Past results do not predict the next one.
How much does AVTX move around earnings?
Over its last 4 reports the stock moved an average of 3.8% (absolute, from the close before the report day to the close after it), and finished higher 2 of 4 times.
Did Avalo Therapeutics beat earnings estimates last quarter?
Avalo Therapeutics last reported on Aug 6, 2026: EPS of -$0.83 against an estimate of -$0.62 (-33.9% surprise), a miss.
How much does AVTX usually move in a day?
On a normal trading day the ATLAS model puts AVTX’s one-day range at about ±9.2%, with a 48% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer